Radiosurgery and Immunotherapy for Melanoma Patients With Brain Metastases

Video

In this video we discuss the use of concurrent immunotherapy and stereotactic radiosurgery for treatment of melanoma brain metastases.

A new retrospective study found that patients with melanoma brain metastases who were treated with immunotherapy and stereotactic radiosurgery (SRS) within a month of each other had more robust and rapid tumor shrinkage.

In this video, senior study author Veronica L. S. Chiang, MD, of the Department of Neurosurgery at the Yale School of Medicine in New Haven, Connecticut, discusses the results of the study. Click here to read more.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.